Clinical implications of molecular abnormalities in lung cancer
- 1 October 1998
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 24 (5) , 317-330
- https://doi.org/10.1016/s0305-7372(98)90055-x
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumoursOncogene, 1997
- Clinical implications of telomerase in cancerEuropean Journal Of Cancer, 1997
- The biology of replicative senescenceEuropean Journal Of Cancer, 1997
- No evidence of microsatellite instability but frequent loss of heterozygosity in primary resected lung cancerEnvironmental and Molecular Mutagenesis, 1997
- Cancer Cell CyclesScience, 1996
- Myc—Max—Mad: a transcription factor network controlling cell cycle progression, differentiation and deathCurrent Opinion in Genetics & Development, 1994
- Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomasZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Apoptosis of Lung Cancer Cells Caused by Some Anti-cancer Agents (MMC, CPT-11, ADM) is Inhibited by BCL-2Biochemical and Biophysical Research Communications, 1993
- Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinomaEuropean Journal of Cancer and Clinical Oncology, 1991
- Chromosome 17 Deletions and p53 Gene Mutations in Colorectal CarcinomasScience, 1989